History

NĒRx Biosciences was founded in 2009 by John Turchi, Ph.D, (President and CSO) and Robert Feltgen. Our pipeline of small molecule inhibitors (SMIs) is based on the discoveries from Dr. Turchi’s lab at the Indiana University School of Medicine. His work over the past two decades in studying DNA damage and repair has dramatically advanced our understanding of genome instability and DNA repair in cancer treatment. The culmination of this academic research was the discovery of a series of SMIs that inhibit the DNA binding activity of specific DNA damage sensor proteins. NĒRx has an exclusive license to these and future discoveries from the Turchi lab and focuses on their clinical development and commercialization. Our ultimate goal is to develop novel therapeutics to enable the effective treatment of highly prevalent and difficult-to-treat cancers including lung and ovarian.